2025-11-06 - Analysis Report
Okay, here's the analysis of Recursion Pharmaceuticals (RXRX) based on the data you provided.

## RXRX Stock Analysis

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -18.57%
*   **VOO Cumulative Return:** 41.50%
*   **Absolute Divergence:** -50.07%
*   **Relative Divergence:** 9.2

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period considered. The relative divergence of 9.2 suggests that RXRX is currently near the bottom of its historical performance range compared to the S&P 500.

### 2. Alpha, Beta Analysis

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2021-2023  | 22.0%   | 81.0%  | 26.0%   | -0.2  | 4.3    |
| 2022-2024  | 11.0%   | 81.0%  | -10.0%  | 0.1   | 3.0    |
| 2023-2025  | 24.0%   | 80.0%  | -40.0%  | 0.1   | 2.2    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows inconsistent growth.
*   **MDD:** High Maximum Drawdown (MDD) indicates significant risk and volatility.
*   **Alpha:** Alpha is inconsistent, declining sharply recently. This suggests underperformance relative to the benchmark.
*   **Beta:** Low Beta values suggest RXRX is not strongly correlated with the overall market (S&P 500).
*   **Cap(B):** The market capitalization shows a decline over the periods considered.

### 3. Recent Stock Price Movements

*   **Current Price:** 5.0799
*   **Last Market Data:** {'price': 5.075, 'previousClose': 5.0, 'change': 1.5} (This data indicates a significant recent price increase.)
*   **5-day Moving Average:** 5.512
*   **20-day Moving Average:** 5.8675
*   **60-day Moving Average:** 5.2655

**Analysis:** The stock price is currently below its 5-day and 20-day moving averages but above its 60-day moving average. The recent price increase, as indicated by the "Last Market Data," suggests a short-term upward trend or a potential rebound. The price is experiencing a near 1.5% change compared to the previous close.

### 4. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 30.96
*   **PPO:** -2.31
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90) Monthly invest 1.8% of total investment ($1,000.00)
*   **20-day Relative Divergence Change:** -4.8 (Negative: Short-term Decline)
*   **Expected Return:** -44.5% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** While the MRI suggests a high investment recommendation based on the model, it should be considered alongside other indicators.
*   **RSI:** An RSI of 30.96 suggests the stock is nearing "oversold" territory, potentially indicating a buying opportunity.
*   **PPO:** The negative PPO suggests a downward trend.
*   **Hybrid Signal:** The signal recommends buying with available cash and continuing monthly investments.
*   **20-day Relative Divergence Change:** The negative change indicates recent underperformance.
*   **Expected Return:** The highly negative expected return suggests significant long-term underperformance compared to the S&P 500, making it a high-risk investment.

### 5. Recent News & Significant Events

*   **CEO Transition:** The company has named Najat Khan as Chief Executive and President. This could signal a new strategic direction.
*   **Q3 Earnings Miss:** Recent news indicates that Recursion Pharmaceuticals missed revenue estimates and reported a wider loss in Q3.
*   **Business Update:** Recursion provided a business update alongside the earnings report, which may contain important insights into the company's future plans and challenges.

**Analysis:** The CEO transition and Q3 earnings miss are significant events that likely contributed to the recent stock price volatility. Investors will be closely watching the new CEO's strategy and the company's ability to improve its financial performance.

### 6. Analyst Opinions

*   **Consensus:** Hold
*   **Mean Rating:** 2.62 (~Hold)
*   **Number of Opinions:** 6
*   **Target Price (avg/high/low):** 6.47 / 10.00 / 3.00
*   **Recent Rating Changes:** (No Specific Changes Provided)

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook on the stock. The average target price of $6.47 indicates a potential upside from the current price, but the range is wide ($3.00 - $10.00), reflecting uncertainty among analysts.

### 7. Earnings Analysis

| Date       | EPS   | Revenue   |
|------------|-------|-----------|
| 2025-11-05 | -0.36 | 0.01 B$   |
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.50 | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2025-11-05 | -0.34 | 0.03 B$   |

**Analysis:** The company consistently reports negative EPS, and revenue has fluctuated. This suggests that the company is not yet profitable and relies on external funding.

### 8. Financial Information

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.02B   | -5.54%        |
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-06-30 | $0.92B   | -18.70%  |
| 2025-03-31 | $0.93B   | -21.68%  |
| 2024-12-31 | $1.03B   | -17.29%  |
| 2024-09-30 | $0.52B   | -18.27%  |
| 2024-06-30 | $0.58B   | -16.69%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue is inconsistent, and the profit margin is generally negative, except for two quarters in 2024.
*   **Capital and Profitability:** Equity has fluctuated, and ROE is consistently negative, indicating that the company is not generating profits from its equity.

### 9. Summary

RXRX is a high-risk, high-potential investment. The company is underperforming the S&P 500, showing inconsistent financial performance, and is not yet profitable. Recent news indicates a CEO transition and Q3 earnings miss. However, the company's focus on AI-driven drug discovery and the potential for breakthroughs in its clinical pipeline could lead to significant future gains. Analyst consensus is "Hold," with a wide target price range, reflecting uncertainty. Based on the provided data, a cautious approach is warranted, and potential investors should carefully consider their risk tolerance and conduct further due diligence.

